Turning Pathways on Their Head: Deimplementation of Low-Value Treatment Regimens

Rapid advancements in oncology have led to an exponential rise in treatment costs, making the value proposition of anticancer agents more impor­tant than ever. Adherence and adoption of recommendations to avoid low-val­ue treatments vary across the cancer continuum. Evolent evaluated the impact of active deimplementation strategies to achieve meaningful reductions in low-value oncology care.